Related Experiment Video
Updated: May 29, 2026
05:35
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
Personalizing CA125 levels for ovarian cancer screening
Oliver Dorigo1, Jonathan S Berek
1Department of Obstetrics and Gynecology, The UCLA David Geffen School of Medicine, Los Angeles, CA, USA. jberek@stanford.edu
Cancer Prevention Research (Philadelphia, Pa.)
|September 7, 2011
Summary
Early ovarian cancer detection using CA125 serum markers shows promise, but baseline levels are influenced by patient factors like menopausal status. Stratifying CA125 cutoff points may reduce false positives in screening.
Area of Science:
- Gynecologic Oncology
- Cancer Screening
- Biomarker Analysis
Background:
- Ovarian cancer screening trials have not yet reduced mortality.
- Current methods like CA125 tests have high false-positive rates.
- The Risk of Ovarian Cancer Algorithm (ROCA) uses CA125 trends and patient age.
Purpose of the Study:
- To analyze baseline CA125 serum marker levels in high-risk ovarian cancer patients.
- To investigate the impact of demographic and clinical factors on CA125 distribution.
- To explore potential improvements in early ovarian cancer diagnosis.
Main Methods:
- Analysis of baseline CA125 serum marker levels.
- Inclusion of high-risk patients from Cancer Genetics Network and Gynecologic Oncology Group trials.
- Examination of demographic and clinical factors, including menopausal status and oral contraceptive use.
Main Results:
- CA125 distribution is significantly affected by menopausal status.
- Oral contraceptive use in premenopausal patients impacts CA125 levels.
- Baseline CA125 levels show variability within high-risk populations.
Conclusions:
- CA125 cutoff points may require stratification by patient subgroups to minimize false positives.
- Further validation in future ovarian cancer screening trials is necessary.
- Understanding factors influencing CA125 is crucial for improving early detection accuracy.
